|
1
|
Pescetelli I, Zimarino M, Ghirarduzzi A
and De Caterina R: Localizing factors in atherosclerosis. J
Cardiovasc Med (Hagerstown). 16:824–830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yusuf S, Hawken S, Ounpuu S, Dans T,
Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, et al:
Effect of potentially modifiable risk factors associated with
myocardial infarction in 52 countries (the INTERHEART study):
Case-control study. Lancet. 364:937–952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weber C and Noels H: Atherosclerosis:
Current pathogenesis and therapeutic options. Nat Med.
17:1410–1422. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Napoli C: Oxidation of LDL, atherogenesis,
and apoptosis. Ann N Y Acad Sci. 1010:698–709. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu J, Mitra S, Wang X, Khaidakov M and
Mehta JL: Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in
atherogenesis and tumorigenesis. Antioxid Redox Signal.
15:2301–2333. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geng YJ: Biologic effect and molecular
regulation of vascular apoptosis in atherosclerosis. Curr
Atheroscler Rep. 3:234–242. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cai H and Harrison DG: Endothelial
dysfunction in cardiovascular diseases: The role of oxidant stress.
Circ Res. 87:840–844. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abifadel M, Guerin M, Benjannet S, Rabès
JP, Le Goff W, Julia Z, Hamelin J, Carreau V, Varret M, Bruckert E,
et al: Identification and characterization of new gain-of-function
mutations in the PCSK9 gene responsible for autosomal dominant
hypercholesterolemia. Atherosclerosis. 223:394–400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roth EM, McKenney JM, Hanotin C, Asset G
and Stein EA: Atorvastatin with or without an antibody to PCSK9 in
primary hypercholesterolemia. N Engl J Med. 367:1891–1900. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee P and Hegele RA: Current Phase II
proprotein convertase subtilisin/kexin 9 inhibitor therapies for
dyslipidemia. Expert Opin Investig Drugs. 22:1411–1423. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poirier S and Mayer G: The biology of
PCSK9 from the endoplasmic reticulum to lysosomes: New and emerging
therapeutics to control low-density lipoprotein cholesterol. Drug
Des Devel Ther. 7:1135–1148. 2013.PubMed/NCBI
|
|
12
|
Leren TP: Sorting an LDL receptor with
bound PCSK9 to intracellular degradation. Atherosclerosis.
237:76–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Constantinides A, Kappelle PJ, Lambert G
and Dullaart RP: Plasma lipoprotein-associated phospholipase A2 is
inversely correlated with proprotein convertase subtilisin-kexin
type 9. Arch Med Res. 43:11–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Libby P, Ridker PM and Maseri A:
Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rioufol G, Finet G, Ginon I, André-Fouët
X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF and Tabib A:
Multiple atherosclerotic plaque rupture in acute coronary syndrome:
A three-vessel intravascular ultrasound study. Circulation.
106:804–808. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gu HF, Tang CK and Yang YZ: Psychological
stress, immune response, and atherosclerosis. Atherosclerosis.
223:69–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hansson GK: Inflammation, atherosclerosis,
and coronary artery disease. N Engl J Med. 352:1685–1695. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Simionescu M and Antohe F: Functional
ultrastructure of the vascular endothelium: Changes in various
pathologies. Handb Exp Pharmacol. 41–69. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kwon GP, Schroeder JL, Amar MJ, Remaley AT
and Balaban RS: Contribution of macromolecular structure to the
retention of low-density lipoprotein at arterial branch points.
Circulation. 117:2919–2927. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Benn M, Nordestgaard BG, Grande P, Schnohr
P and Tybjaerg-Hansen A: PCSK9 R46L, low-density lipoprotein
cholesterol levels, and risk of ischemic heart disease: 3
independent studies and meta-analyses. J Am Coll Cardiol.
55:2833–2842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Yuan F, Liu P, Fei L, Huang Y, Xu
L, Hao L, Qiu X, Le Y, Yang X, et al: Association between PCSK9 and
LDLR gene polymorphisms with coronary heart disease: Case-control
study and meta-analysis. Clin Biochem. 46:727–732. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu NQ and Li JJ: PCSK9 gene mutations and
low-density lipoprotein cholesterol. Clin Chim Acta. 431:148–153.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Huang Y, Hobbs HH and Cohen JC:
Molecular characterization of proprotein convertase
subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid
Res. 53:1932–1943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tavori H, Fan D, Blakemore JL, Yancey PG,
Ding L, Linton MF and Fazio S: Serum proprotein convertase
subtilisin/kexin type 9 and cell surface low-density lipoprotein
receptor: Evidence for a reciprocal regulation. Circulation.
127:2403–2413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen MA, Kosenko T and Lagace TA:
Internalized PCSK9 dissociates from recycling LDL receptors in
PCSK9-resistant SV-589 fibroblasts. J Lipid Res. 55:266–275. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang DW, Lagace TA, Garuti R, Zhao Z,
McDonald M, Horton JD, Cohen JC and Hobbs HH: Binding of proprotein
convertase subtilisin/kexin type 9 to epidermal growth factor-like
repeat A of low density lipoprotein receptor decreases receptor
recycling and increases degradation. J Biol Chem. 282:18602–18612.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mousavi SA, Berge KE and Leren TP: The
unique role of proprotein convertase subtilisin/kexin 9 in
cholesterol homeostasis. J Intern Med. 266:507–519. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Plump AS and Breslow JL: Apolipoprotein E
and the apolipoprotein E-deficient mouse. Annu Rev Nutr.
15:495–518. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Getz GS and Reardon CA: Animal models of
atherosclerosis. Arterioscler Thromb Vasc Biol. 32:1104–1115. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jorgensen RA: Cosuppression, flower color
patterns, and metastable gene expression states. Science.
268:686–691. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Elbashir SM, Martinez J, Patkaniowska A,
Lendeckel W and Tuschl T: Functional anatomy of siRNAs for
mediating efficient RNAi in Drosophila melanogaster embryo lysate.
EMBO J. 20:6877–6888. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Onat D, Brillon D, Colombo PC and Schmidt
AM: Human vascular endothelial cells: A model system for studying
vascular inflammation in diabetes and atherosclerosis. Curr Diab
Rep. 11:193–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Berens HM and Tyler KL: The proapoptotic
Bcl-2 protein Bax plays an important role in the pathogenesis of
reovirus encephalitis. J Virol. 85:3858–3871. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sanz AB, Santamaría B, Ruiz-Ortega M,
Egido J and Ortiz A: Mechanisms of renal apoptosis in health and
disease. J Am Soc Nephrol. 19:1634–1642. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Chen N, Zhang J and Tong Y:
Hsa-let-7g miRNA targets caspase-3 and inhibits the apoptosis
induced by ox-LDL in endothelial cells. Int J Mol Sci.
14:22708–22720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aplin AE, Hogan BP, Tomeu J and Juliano
RL: Cell adhesion differentially regulates the nucleocytoplasmic
distribution of active MAP kinases. J Cell Sci. 115:2781–2790.
2002.PubMed/NCBI
|
|
39
|
Weston CR and Davis RJ: The JNK signal
transduction pathway. Curr Opin Genet Dev. 12:14–21. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Poulikakos PI, Persaud Y, Janakiraman M,
Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al:
RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E). Nature. 480:387–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Krens SF, Spaink HP and Snaar-Jagalska BE:
Functions of the MAPK family in vertebrate-development. FEBS Lett.
580:4984–4990. 2006. View Article : Google Scholar : PubMed/NCBI
|
